Generex Biotechnology Corp. (OTC: GNBT): Building a billion dollar next-generation healthcare business.

Joe Moscato, CEO, Generex Biotechnology Corp.
Joe Moscato, CEO, Generex Biotechnology Corp.

 

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

 

 

 

 

Generex Biotechnology Corp. (OTC: GNBT) Interview with CEO Joe Moscato. Joe shares an update on the continued transformation of Generex into a next-generation integrated pharmaceutical healthcare business, through strategic acquisitions. Generex’s recent acquisition of medical services assets is generating over $75 million in revenues  and is expect to generate over $1 billion annual revenues, as it expands to multiple states over the next 18 months. 

Joe Moscato outlines the corporate growth strategy, which is focused on strategic acquisitions of revenue-generating healthcare assets, including: services, pharmaceuticals and medical devices, and maximizing shareholder value through spin-out’s and dividends.

Discussion also includes an update on Generex’s clinical-stage immuno-oncology assets, which are being developed in partnerships with Merck and Shenzhen BioScien, and address billion dollar market opportunities.

 

Investor Presentation

Generex presentation